Personal information

No personal information available

Activities

Collapse all

Works (50 of 92)

Items per page:
Page 1 of 2

Impact of Vein-to-vein Time in Patients With R/R LBCL Treated With Axicabtagene Ciloleucel

Blood Advances
2025-01-30 | Journal article
DOI: 10.1182/bloodadvances.2024013656
Contributors: Frederick L Locke; Tanya Siddiqi; Caron A. Jacobson; Sarah Nikiforow; Sairah Ahmed; David B Miklos; Yi Lin; Matthew A Lunning; Brian T. Hill; Armin Ghobadi et al.
Source: check_circle
Crossref

Data from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.c.6879431
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Data from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.c.6879431.v2
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033949
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033949.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033946
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033946.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033943
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033943.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S4 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033940.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S4 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033940
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S5 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033937
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S5 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033937.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S6 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033934
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S6 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033934.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S7 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033931
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S7 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033931.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S8 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033928
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S8 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033928.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033925.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033925
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Table S1 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033922.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Table S1 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033922
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Table S2 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033919.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Table S2 from Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27033919
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood
2024-06-27 | Journal article
DOI: 10.1182/blood.2023023447
Contributors: Frederick L. Locke; Tanya Siddiqi; Caron A. Jacobson; Armin Ghobadi; Sairah Ahmed; David B. Miklos; Miguel-Angel Perales; Javier Munoz; Warren B. Fingrut; Martina Pennisi et al.
Source: check_circle
Crossref

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

Blood Advances
2024-06-11 | Journal article
DOI: 10.1182/bloodadvances.2023011532
Contributors: Armin Ghobadi; Javier Munoz; Jason R. Westin; Frederick L. Locke; David B. Miklos; Aaron P. Rapoport; Miguel-Angel Perales; Patrick M. Reagan; Joseph McGuirk; Caron A. Jacobson et al.
Source: check_circle
Crossref

Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study

Bone Marrow Transplantation
2024-03 | Journal article
DOI: 10.1038/s41409-023-02168-0
Contributors: Philip L. McCarthy; Kristopher M. Attwood; Xiaojun Liu; George L. Chen; Hans Minderman; Amin Alousi; Asad Bashey; Robert Lowsky; David B. Miklos; John Hansen et al.
Source: check_circle
Crossref

Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD

Blood Advances
2024-03-12 | Journal article
DOI: 10.1182/bloodadvances.2023011625
Contributors: Cameron S. Bader; Anna Pavlova; Robert Lowsky; Lori S. Muffly; Parveen Shiraz; Sally Arai; Laura J. Johnston; Andrew R. Rezvani; Wen-Kai Weng; David B. Miklos et al.
Source: check_circle
Crossref

Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas

Blood Advances
2024-02-13 | Journal article
DOI: 10.1182/bloodadvances.2023011997
Contributors: Navika D. Shukla; Joseph G. Schroers-Martin; Brian J. Sworder; Karan Raj Kathuria; Stefan K. Alig; Matthew J. Frank; David B. Miklos; Steven Coutre; Maximilian Diehn; Michael S. Khodadoust et al.
Source: check_circle
Crossref

Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Clinical Cancer Research
2023-10-13 | Journal article
DOI: 10.1158/1078-0432.CCR-23-0916
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Data from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.c.6879431.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304961
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304961.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304958
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S2 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304958.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304955
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S3 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304955.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S4 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304952
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S4 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304952.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S5 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304949
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S5 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304949.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S6 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304946
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S6 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304946.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S7 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304943
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S7 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304943.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S8 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304940
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Figure S8 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304940.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304937
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref

Supplementary Methods S1 from Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

2023-10-13 | Preprint
DOI: 10.1158/1078-0432.24304937.v1
Contributors: Michael D. Jain; David B. Miklos; Caron A. Jacobson; John M. Timmerman; Jennifer Sun; Jenny Nater; Xiang Fang; Ankit Patel; Madison Davis; Darren Heeke et al.
Source: check_circle
Crossref
Items per page:
Page 1 of 2

Peer review (1 review for 1 publication/grant)

Review activity for The lancet. (1)
How many people are using ORCID?